Survodutide Phase 3: 16% Weight Loss, How It Compares to Zepbound
Share on Pinterest A new GLP-1 drug shows promise for improving metabolic health and treating obesity-related diseases like liver disease. camacho9999/Getty Images A new weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which stimulates GLP-1 and glucagon receptors, led to a 16.6% drop in body weight.